TO THE EDITOR:
We are alarmed by McCance-Katz and Valdiserri's statements that “the best outcomes occur in persons who have ceased injection and other drug use,” Medicaid restrictions based on drug and alcohol criteria are “necessary due to the high cost of hepatitis C virus (HCV) treatment,” and persons with a history of injection drug use should be advised to continue opioid-substitution therapy (OST) “indefinitely” (1). There is no rationale for establishing a salient difference between persons with HCV infection who do and do not use alcohol, drugs, or both (2). As international recommendations highlight (3), HCV treatment is effective ...
References
- 1.
McCance-Katz EF ,Valdiserri RO . Hepatitis C virus treatment and injection drug users: it is time to separate fact from fiction. Ann Intern Med. 2015;163:224-5. [PMID:26120801 ]. doi:10.7326/M15-0007 LinkGoogle Scholar - 2.
Grebely J ,Haire B ,Taylor LE ,Macneill P ,Litwin AH ,Swan T ,et al ;International Network for Hepatitis in Substance Users . Excluding people who use drugs or alcohol from access to hepatitis C treatments—is this fair, given the available data? [Editorial]. J Hepatol. 2015;63:779-82. [PMID:26254264 ] doi:10.1016/j.jhep.2015.06.014 CrossrefMedlineGoogle Scholar - 3.
Grebely J ,Robaeys G ,Bruggmann P ,Aghemo A ,Backmund M ,Bruneau J ,et al ;International Network for Hepatitis in Substance Users . Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:1028-38. [PMID:26282715 ] doi:10.1016/j.drugpo.2015.07.005 CrossrefMedlineGoogle Scholar - 4.
Aspinall EJ ,Corson S ,Doyle JS ,Grebely J ,Hutchinson SJ ,Dore GJ ,et al . Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57 Suppl 2:S80-9. [PMID:23884071 ] doi:10.1093/cid/cit306 CrossrefMedlineGoogle Scholar - 5.
Barua S ,Greenwald R ,Grebely J ,Dore GJ ,Swan T ,Taylor LE . Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163:215-23. [PMID:26120969 ]. doi:10.7326/M15-0406 LinkGoogle Scholar
Author, Article and Disclosure Information
From The Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia; Center for Health Law and Policy Innovation, Harvard Law School, Cambridge, Massachusetts; Treatment Action Group, New York, New York; Brown University, Providence, Rhode Island; Brown University and Miriam Hospital, Providence, Rhode Island.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L15-0485.
Financial Support: The Kirby Institute is funded by the Australian Government Department of Health and Ageing. Dr. Grebely is supported by a National Health and Medical Research Council Career Development Fellowship. Mr. Greenwald is supported by Harvard Law School. Dr. Taylor is supported by a Rhode Island Innovation Fellowship from the Rhode Island Foundation for her Rhode Island Defeats Hep C project and the Lifespan/Tufts/Brown Center for AIDS Research (grant P30AI042853 from the National Institute of Allergy and Infectious Diseases). Ms. Barua was supported by the Lifespan/Tufts/Brown Center for AIDS Research Summer Student Internship program (grant P30AI042853).
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.